EVIDENCE FOR ALTERED OPIOID ACTIVITY IN PATIENTS WITH CANCER
EVIDENCE FOR ALTERED OPIOID ACTIVITY IN PATIENTS WITH CANCER
复制标题
DOI：
10.1038/bjc.1987.300
复制
发表时间：
1987-12-01
影响因子：
8.8
通讯作者：
TANCINI, G
中科院分区：
文献类型：
--
作者：
LISSONI, P;BARNI, S;TANCINI, G
内源性阿片肽已被证明参与肿瘤生长的调节。然而，目前还没有关于癌症患者阿片肽分泌的数据。为了得出一些关于阿片类药物在人类肿瘤中的脑功能的初步结论，我们评估了垂体激素对甲硫氨酸脑啡肽类似物FK 33-824给药的反应。该研究包括14名受早期或晚期肿瘤疾病影响的患者，12名健康受试者和7名患有癌症以外的慢性疾病的患者。FK 33 -824以0.3 mg剂量静脉给药。分别在给药后0、30、60和120 min采集静脉血标本。在每个样品中，PRL、GH、LH、皮质醇和β-用放射免疫法测定内啡肽水平。在所有正常受试者和患有非肿瘤性慢性疾病的患者中，FK 33-824诱导PRL和GH水平的升高，以及LH、皮质醇和β-雌二醇水平的降低。内啡肽仅在一名癌症患者中观察到对FK 33-824的正常内分泌反应，而在其他肿瘤病例中，在FK 33-824后未观察到激素变化或反常反应。基于在下丘脑-垂体疾病中描述了对FK 33-824的异常内分泌反应的事实，其中异常的脑阿片样物质活性已被证实，这些结果表明癌症患者中存在阿片样物质系统功能改变，其临床重要性仍有待确定。
Endogenous opioid peptides have been shown to be involved in the regulation of tumour growth. At present, however, no data are available about the secretion of opioid peptides in cancer patients. To draw some preliminary conclusions on opioid brain function in human neoplasms, we evaluated hypophyseal hormone responses to the administration of a met-enkephalin analogue, FK 33-824. The study included 14 patients affected by early or advanced neoplastic disease, 12 healthy subjects and 7 patients with a chronic medical illness other than cancer. FK33-824 was given intravenously at a dose of 0.3 mg. Venous blood samples were collected at zero time, and 30, 60 and 120 min after drug administration. In each sample, PRL, GH, LH, cortisol and .beta.-endorphin levels were measured by RIA. In all normal subjects and in patients with non-neoplastic chronic illness, FK 33-824 induced a rise in PRL and GH levels, and a decrease in LH, cortisol and .beta.-endorphin. A normal endocrine response to FK 33-824 was seen in one cancer patient only, while in the other cases with tumour no hormonal changes or a paradoxical response were seen after FK 33-824. Based on the fact that an abnormal endocrine response to FK 33-824 has been described in hypothalamic-pituitary disorders, in which anomalous brain opioid activity has been demonstrated, these results suggest the existence of an altered function of the opioid system in cancer patients, the clinical importance of which remains to be determined.